The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
about
Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic reviewHarnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosisImpact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesHIV drug resistance surveillance using pooled pyrosequencingHIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically highNational prevalence and trends of HIV transmitted drug resistance in MexicoOptimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settingsLow prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, RwandaHIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of AngolaEarly warning indicators for HIV drug resistance in Cameroon during the year 2010HIV drug resistance early warning indicators in Namibia for public health actionComparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian PatientsLow primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaHIV drug resistance early warning indicators in namibia with updated World Health Organization guidanceDevelopment, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patientsThe prevalence of HIV-1 drug resistance among antiretroviral treatment naïve individuals in mainland China: a meta-analysisTransmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in IranEpidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance MutationsVirological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaThe origin and evolutionary history of HIV-1 subtype C in SenegalThe challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.Transmitted drug resistance in nonsubtype B HIV-1 infection.Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in ChinaRe-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system.Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort studyGenetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, MozambiqueEvaluation of three sampling methods to monitor outcomes of antiretroviral treatment programmes in low- and middle-income countriesEvaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveysSignificance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratoriesPerformance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India.Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).Field study of dried blood spot specimens for HIV-1 drug resistance genotypingHow HIV treatment could result in effective preventionPrimary drug resistance in South Africa: data from 10 years of surveys.Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.
P2860
Q26823588-8AB777BA-C79A-463A-A0E9-1D9FFA20FE92Q26828443-6B57E366-0FE3-4634-A468-92EC57F15C70Q26851997-93975ABA-692F-4534-A8BF-2274DB5894E1Q28472938-3CB13FC9-8D3A-44A2-83F0-936C40C428EAQ28476627-ACB947B6-B654-4993-AFAE-08FD24DF5C0DQ28477977-68D7AF50-5F49-4CF5-A6B5-CD26F85CBE38Q28478154-68DEBF7F-1307-4770-BD81-04C6678327A5Q28481603-F5A3C8F4-C1DB-4441-AA2B-9C14BE1A9A87Q28482242-58902727-74DD-4209-B743-C4CF9B2512B1Q28482995-F94B6030-D0AB-4FC5-8D89-437A2B02738BQ28483799-95C9A2C6-632D-4818-AB98-F8967F48A7D7Q28533732-D4906899-7354-4759-9681-3497B8A93CFDQ28534376-B7660758-EA92-4E8D-A30D-0ACE57B6F035Q28535266-D5A44E6D-3486-44FD-805E-37D8FE5C9D53Q28540264-202EE3C1-069D-4586-A135-AB6E4495E130Q28542561-F53C718F-E280-4179-8469-2A53975149D8Q28544113-0A74F8CA-2390-410E-AD5D-D5B434C9B5BDQ28547171-22D8F761-5F32-4EA6-A922-C86DB556D6E2Q28547497-943BA0AF-9E67-4345-8045-4A8055073E0AQ28551745-4572FC91-65A0-4A7A-881E-E94FBD910DC0Q30414915-C7C23511-2F26-457C-AC74-AFDCD49C388BQ30425595-49A5AEC7-80B9-47D2-A9DB-4547DF010AF9Q31114921-F9A2D9E9-A02D-405F-A074-87A24D7C279DQ33567164-4B1BFD22-9576-4B9E-8E72-253231CC460CQ33586369-DC7CAC92-2E0B-4881-86A2-EE624C4421E1Q33625404-96D3B2D5-46E0-41A5-A4D2-4C260C0C2859Q33637867-6E9C280B-C710-40A6-8031-BA30008150DEQ33713862-E45C3373-2171-4657-BFAF-3DE7EF9437CFQ33750295-E23F7E5E-6CBA-4B75-8909-1A2E557C21F8Q33791635-E26C9D0F-0B1D-4DF6-966A-96A6B59A797FQ33798584-5BE470F3-D577-4B42-95C6-00B5A98BF55DQ33810988-3074AED0-5F0E-4276-8F4C-6B6B926B3636Q33824827-22ECE01E-522A-4B1F-882C-ED2A55E8C787Q33849840-F9568B3B-A4B3-491F-872E-AD66C93683C9Q33991040-45DE4EE4-480C-4C93-893F-5FD8BD9CF51DQ34040080-DA1558C9-30EF-471C-8AD0-401BCC0C0051Q34058841-DFFEFBD5-A2D6-4B7E-AE4C-BC15EE0FAA1EQ34090397-76C94736-1243-4052-A13F-4C9757BEEF2BQ34129300-7352F4C8-FE4D-4D8F-A596-FC6F4D106720Q34283361-CAA02E56-1637-40AC-9E0C-6BED10A439C2
P2860
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The World Health Organization' ...... ssment of HIV drug resistance.
@en
The World Health Organization' ...... ssment of HIV drug resistance.
@nl
type
label
The World Health Organization' ...... ssment of HIV drug resistance.
@en
The World Health Organization' ...... ssment of HIV drug resistance.
@nl
prefLabel
The World Health Organization' ...... ssment of HIV drug resistance.
@en
The World Health Organization' ...... ssment of HIV drug resistance.
@nl
P2093
P921
P1433
P1476
The World Health Organization' ...... essment of HIV drug resistance
@en
P2093
Charles F Gilks
Diane E Bennett
Donald Sutherland
Silvia Bertagnolio
P478
13 Suppl 2
P577
2008-01-01T00:00:00Z